Medicare and GLP-1 Medications: What's Covered, What Isn't, and What You Can Do
May 2026 | BetterNewLives.com
If you're on Medicare and trying to access Ozempic, Wegovy, Mounjaro, or Zepbound, you're facing one of the most frustrating coverage situations in American healthcare. The rules are strict, the workarounds are limited, and the savings cards that help everyone else don't work for you. This guide explains exactly why — and what options you actually have.
What Medicare Part D Actually Covers
Medicare Part D is the prescription drug benefit. Its coverage of GLP-1 medications follows a strict diabetes vs. weight-loss distinction:
| Drug | FDA Indication | Medicare Part D | Notes |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | Covered | Covered when prescribed for diabetes. May require PA. Cost-sharing applies. |
| Mounjaro (tirzepatide) | Type 2 diabetes | Covered | Covered for diabetes indication. Increasingly common on Part D formularies. |
| Wegovy (semaglutide) | Chronic weight management | Not covered | Federally prohibited from Part D coverage regardless of clinical need. |
| Zepbound (tirzepatide) | Chronic weight management | Not covered | Same active ingredient as Mounjaro, but the weight-loss label disqualifies it. |
| Rybelsus (oral semaglutide) | Type 2 diabetes | Covered | Covered for diabetes. Oral form — no injection required. |
| Victoza / Trulicity (older GLP-1s) | Type 2 diabetes | Covered | Older drugs, well-established on formularies. Less weight-loss effect. |
Why This Coverage Gap Exists: The Legal Backstory
The prohibition on Medicare covering weight-loss drugs dates to 1987 — long before GLP-1 medications existed. Congress wrote a list of drug categories that Medicare Part D could not cover, and "drugs used for anorexia, weight loss, or weight gain" was on that list.
At the time, this made sense: the weight-loss drugs of that era had poor efficacy and real safety concerns. No one anticipated that a class of medications would emerge decades later that could produce 15–22% body weight reductions while also reducing cardiovascular events, improving kidney function, and lowering mortality risk in clinical trials.
The law has not been updated. As of 2026, GLP-1 drugs approved specifically for weight management remain ineligible for Medicare Part D coverage — even though the same molecules, prescribed under a different indication, are fully covered.
The Manufacturer Savings Card Problem
This is the issue that catches many Medicare beneficiaries off guard. For commercially insured patients, manufacturer savings cards are a major cost-reduction tool — bringing Mounjaro or Zepbound to as little as $25/month. But these cards cannot be used with Medicare.
The reason is the federal Anti-Kickback Statute (AKS). This law prohibits pharmaceutical companies from offering "remuneration" — including discounts and coupons — to Medicare beneficiaries as an inducement to purchase drugs covered by the federal program. The savings cards would reduce Medicare's cost-sharing obligations, which could be interpreted as an illegal kickback to induce Medicare spending.
The key points for Medicare beneficiaries:
- Lilly's $25/month savings card for Mounjaro or Zepbound: not available to Medicare patients
- Novo Nordisk's savings card for Ozempic or Wegovy: not available to Medicare patients
- This prohibition applies even if you're on Medicare Advantage
- It applies even if you're also enrolled in a Medigap supplement plan
- Attempting to use these cards while on Medicare creates legal risk
What Medicare Patients Can Actually Do
If you have type 2 diabetes
Work with your doctor to ensure you're prescribed the diabetes-indication drug (Ozempic, Mounjaro). These are Part D-covered. You'll still face formulary restrictions, prior auth, and cost-sharing — but coverage is legally available to you.
Patient Assistance Programs
Lilly Cares Foundation and the Novo Nordisk Patient Assistance Program provide free medication to eligible patients — including Medicare beneficiaries who meet income thresholds. These are legal for Medicare patients, unlike savings cards.
Telehealth + Self-Pay
Medicare beneficiaries may enroll in telehealth weight-loss programs (Found, Hims & Hers, Ro Body, etc.) on a self-pay basis — entirely outside of Medicare. Costs run $99–$399/month for compounded GLP-1. No Medicare involvement required.
Advocacy: Support TROA
The Treat and Reduce Obesity Act would change all of this. Contact your Congressional representatives and support advocacy organizations working to pass this legislation. For the 65 million Medicare beneficiaries affected, this law matters.
Patient Assistance Programs: The Legal Option for Low-Income Medicare Patients
Unlike savings cards, patient assistance programs (PAPs) are structured to comply with Anti-Kickback rules. They are designed specifically for patients who cannot afford their medications — including Medicare patients. Here's what's available:
Lilly Cares Foundation
Provides free Mounjaro or Zepbound to eligible patients. Medicare beneficiaries may qualify based on income. Eligibility generally requires income at or below 400% of the federal poverty level. Applications submitted through your prescribing physician. Contact: 1-800-545-5979 or lilly.com/lilly-cares.
Novo Nordisk Patient Assistance Program
Provides free Ozempic or Wegovy to eligible patients, including Medicare beneficiaries. Income-based eligibility. Contact: 1-866-310-7549 or novonordisk-us.com/patients/patient-assistance.html.
NeedyMeds & RxAssist
Free databases that catalog all available PAPs and eligibility requirements. NeedyMeds.org and RxAssist.org both allow you to search by drug name. These services are free to use and can help you identify programs you may not be aware of.
The Telehealth Self-Pay Option in Detail
Many Medicare beneficiaries don't realize that telehealth programs operate completely outside of Medicare. When you pay out of pocket for a weight-loss program, you're functioning as a self-paying patient — Medicare doesn't enter into the transaction at all.
This means:
- You can enroll in Found, Hims & Hers, Ro Body, Henry Meds, or similar programs as a self-pay patient
- Medicare is not billed and has no involvement
- You receive compounded semaglutide or tirzepatide from a licensed compounding pharmacy
- Costs range from approximately $99–$499/month depending on the program and medication
- You do not use your Medicare Part D benefit for this — it's entirely self-pay
The tradeoff: you're paying out of pocket for medication that other patients get covered, and the compounded versions carry different quality considerations than brand-name drugs. See our Compounded GLP-1 Guide for what to look for in a compounding pharmacy.
If You Have a Diabetes Diagnosis: Navigating Part D Coverage
For Medicare beneficiaries with type 2 diabetes, GLP-1 coverage through Part D is possible. Here's how to approach it:
- Check your Part D plan's formulary. Log into Medicare.gov or call your plan directly. Look for Ozempic (semaglutide) and Mounjaro (tirzepatide) on the formulary. Note the tier they're on — Tier 4 or 5 specialty drugs will have higher cost-sharing than Tier 1–3.
- Ask your prescriber to document the diabetes indication. Ensure the prescription and clinical notes clearly reflect the type 2 diabetes diagnosis and the clinical rationale for this specific GLP-1 over other diabetes medications. The PA reviewer will be looking for this.
- Apply for Extra Help (Low Income Subsidy) if you qualify. The Social Security Administration's Extra Help program can dramatically reduce your Part D cost-sharing — sometimes to zero. In 2026, individuals with income up to ~$21,000/year and limited assets may qualify. Apply at SSA.gov or call 1-800-772-1213.
- Request prior authorization if required. Your prescribing doctor's office submits the PA. The documentation should include your diabetes diagnosis (ICD-10 E11.x), your HbA1c levels, current medications, and the clinical rationale. Most PAs for Ozempic or Mounjaro for diabetes are approved when properly documented.
- Appeal any denial in writing. If your Part D plan denies coverage, request a written explanation and appeal. For Medicare denials, you have the right to request an Independent Review Entity (IRE) review. The Medicare Rights Center (medicarerights.org) provides free counseling and appeal assistance.
The Prediabetes Angle
If your HbA1c falls in the prediabetes range (5.7%–6.4%), this is worth discussing carefully with your doctor. While prediabetes alone may not qualify for the diabetes drug label, a thorough metabolic evaluation may reveal:
- Borderline type 2 diabetes (HbA1c near 6.4%) that could support an E11.x code
- Metabolic syndrome with multiple cardiovascular risk factors
- Strong clinical case for Mounjaro's cardiovascular benefit indication (approved 2024 for CV risk reduction)
Mounjaro received FDA approval in 2024 for reducing cardiovascular risk in people with obesity or overweight and established cardiovascular disease. This cardiovascular indication may open a different coverage pathway. Discuss this with a cardiologist or metabolic specialist if applicable to your situation.
The Treat and Reduce Obesity Act: What It Would Change
The Treat and Reduce Obesity Act (TROA) would amend the Social Security Act to remove anti-obesity medications from the list of excluded drug categories. If passed, it would:
- Allow Medicare Part D plans to cover FDA-approved weight-management medications (including Wegovy and Zepbound)
- Require plans to cover these medications if they cover other chronic disease treatments
- Potentially reduce long-term Medicare costs by preventing obesity-related conditions
- Apply to approximately 65 million Medicare beneficiaries
The bill has been introduced in multiple Congressional sessions and has bipartisan support, but has not yet passed as of 2026. Organizations actively lobbying for its passage include the Obesity Action Coalition, the Obesity Medicine Association, and STOP Obesity Alliance.
If you're a Medicare beneficiary affected by this coverage gap, contacting your Congressional representatives is a meaningful action. Find your representatives at congress.gov/members/find-your-member.